During early brain development mouse Engrailed2 (En2) is expressed in a broad band across most of the mid-hindbrain region. Evidence from gene expression data, promoter analysis in transgenic mice and mutant phenotype analysis in mice and zebra®sh has suggested that Pax2, 5 and 8 play a critical role in regulating En2 mid-hindbrain expression. Previously, we identi®ed two Pax2/5/8-binding sites in a 1.0 kb En2 enhancer fragment that is suf®cient to directed reporter gene expression to the early mid-hindbrain region and showed that the two Pax2/ 5/8-binding sites are essential for the mid-hindbrain expression in transgenic mice. In the present study we have examined the functional requirements of these two Pax2/5/8-binding sites in the context of the endogenous En2 gene for directing mid-hindbrain expression. The two Pax2/5/8-binding sites were deleted from the En2 locus and replaced with the bacterial neo gene by homologous recombination in mouse embryonic stem cells. After transmitting the mutation into mice, the neo gene was removed by breeding with transgenic mice expressing cre from a CMV promoter. Embryos homozygous for this En2 Pax2/5/8-binding site deletion mutation had a mild reduction in En2 expression in the presumptive mid-hindbrain region at the 5-7 somite stage, when En2 expression is normally initiated. However, from embryonic day 9.0 onwards, the mutant embryos showed En2 expression indistinguishable from that seen in wild type embryos. Furthermore, the mutants did not show the cerebellar defect seen in mice with a null mutation in En2. This result demonstrates that the two Pax2/5/8-binding sites that were deleted, while being required for mid-hindbrain expression in the context of a 1.0 kb En2 enhancer, are only required for proper initiation of expression of the endogenous En2 gene. Interestingly, a comparison of the lacZ RNA and protein expression patterns directed by the 1.0 kb enhancer fragment revealed that lacZ protein was acting as a lineage marker in the mid-hindbrain region by persisting longer than the mRNA. The transgene expression directed by the 1.0 kb enhancer fragment therefore does not mimic the entire broad domain of En2 expression. Taken together, these two studies demonstrate that DNA binding sites in addition to the two Pax2/5/8-binding sites must be necessary for En2 mid-hindbrain expression. q
Introduction
Early patterning of the vertebrate central nervous system (CNS) results in regional speci®cation along the anteriorposterior (A-P) axis. Genetic and experimental evidence has indicated that the mesencephalon and metencephalon, (referred to as the mid-hindbrain region) are speci®ed as part of an integrated patterning process that gives rise to the midbrain structures and cerebellum, respectively (reviewed in Wassef and Joyner, 1997) . A growing number of genes, including those that encode the transcription factors Engrailed1 and 2 (En1 and 2), Pax2, Pax5, Pax8, Otx2 and Gbx2, as well as the secreted factors Fgf8 and Wnt1, have been found to be required for development of the midbrain and cerebellum. However, little is known about the epistatic interactions between these developmental regulators and the genetic pathways that control midbrain and cerebellum development. During brain development the two homeobox-containing mouse En genes (Joyner et al., 1985; Joyner and Martin, 1987) are expressed in the midbrain and cerebellum in a spatially and temporally restricted manner (Davidson et al., 1988; Davis et al., , 1991 McMahon et al., 1992) . En1 expression is ®rst detected at the 1 somite stage (embryonic day 8.0, E8.0) in the anterior neuroepithelium, and En2 is expressed in a similar region beginning at the 5 somite stage (E8.5). The early En expression domain appears to mark the presumptive midhindbrain region. After neural tube closure, both En genes are expressed in a broad region surrounding the mid-hindbrain junction, and expression continues in the developing midbrain and cerebellum throughout embryogenesis. Studies of mouse En1 and En2 mutants have shown that both genes are required for normal development of these brain regions. Mice homozygous for an En1 targeted mutant allele die at birth and have an early embryonic (by E9.0) loss of brain tissue that results in deletion of most midbrain and cerebellar structures , in addition to limb defects (Loomis et al., 1996 . Adult mice homozygous for two En2 targeted alleles show a 30% reduction in the size of the cerebellum and a speci®c cerebellar foliation defect Millen et al., 1994) . The two En proteins have been shown to have similar biochemical activities in the brain, since the En1 mutant brain phenotype, but not the postnatal limb defects, can be rescued by replacing En1 with En2 coding sequences (Hanks et al., 1995 (Hanks et al., , 1998 . Furthermore, En1/En2 compound homozygous mutant mice have a deletion of the entire midbrain and cerebellum that is more extensive than the deletion seen in En1 homozygotes (Wurst and Joyner, unpublished) . These En mutant studies indicate that the two En genes normally have overlapping functions in early speci®cation of the mid-hindbrain brain region.
The vertebrate Pax genes, homologues of the Drosophila paired box-containing gene paired (prd), encode a family of transcription factors (reviewed in Gruss and Walther, 1992) . Members of the Pax5 subfamily, including Pax2, 5 and 8 in mouse, as well as the homologous genes in zebra®sh, show overlapping expression with En in the mid-hindbrain region. In mouse, Pax2 expression is detected in the presumptive mid-hindbrain region at the pre-somite stage, preceding En1 expression (Rowitch and McMahon, 1995) . Pax5 expression (Adams et al., 1992; Asano et al., 1992) initiates at about the same time as En2 followed by Pax8 activation at about the 12 somite stage (Stoykova and Gruss, 1994; Song et al., 1996) . From E9.0 to E12.5, the three Pax genes are expressed in domains that overlap with those of the En genes surrounding the mid-hindbrain junction. Single mutations in mouse Pax2 or Pax5 result in mild disruptions of the mid-hindbrain region, whereas double mutants have a loss of most of the midbrain and cerebellum from an early embryonic stage. Two different brain phenotypes have been reported for two Pax2 mouse mutant alleles. Homozygotes for a point mutation allele, Pax2 1Nue , have an early deletion of part of the mid-hindbrain region (Favor et al., 1996) , whereas mice mutant for a targeted N-terminal deletion Pax2 allele have an open neural tube and show exencephaly in the midbrain (Torres et al., 1996) . Pax5 homozygous mutant mice, like En2 mutants, have a relatively mild brain phenotype showing a partial deletion of the inferior colliculus (Urbanek et al., 1994) . Analysis of mice with mutations in Pax2 and 5 has shown that the two genes together are required for formation of the mid-hindbrain region from an early stage (Schwarz et al., 1997 (Schwarz et al., , 1999 Urbanek et al., 1997) .
Zebra®sh have two Pax2-related genes, Pax2.1 and 2.2 (pax2.1 was previously called pax [b] ), and a Pax5 and Pax8 gene and all show restricted expression in the mid-hindbrain region in zebra®sh embryos with Pax2.1 being expressed ®rst (Krauss et al., 1991; Pfeffer et al., 1998) . In contrast to mouse, Pax2.1 expression is required for initiation of expression of the Pax5 and 8 genes (Pfeffer et al., 1998) . Furthermore, zebra®sh embryos homozygous for a Pax2.1 mutant allele, no isthmus (noi), fail to develop a midbrain and cerebellum (Brand et al., 1996) . A similar mid-hindbrain deletion phenotype was elicited by injection of pax-b antibodies into zebra®sh embryos at the two cell stage (Krauss et al., 1992) .
The overlapping expression patterns of the En and Pax genes and the similarities of their mutant brain phenotypes suggest that these genes belong to the same genetic pathway controlling early development of the mid-hindbrain region. Furthermore, genetic analyses in Drosophila have indicated that prd is an important upstream activator of en (reviewed in Hooper and Scott, 1992) . Our previous biochemical and transgenic analysis demonstrated that proteins of the Pax5 subfamily are involved in regulating early En2 mid-hindbrain expression (Song et al., 1996) . A 1.0 kb En2 mid-hindbrain enhancer fragment (En2CX) was shown to be suf®cient to produce lacZ expression in a similar domain to endogenous En2 in transgenic embryos between E8.5 and E12.5. Two DNA sites that speci®cally bind to Pax2, Pax5 and Pax8 proteins were identi®ed within the En2CX enhancer fragment. Deletion of these two Pax2/5/8-binding sites from the En2 enhancer abolished the En2-like transgene expression in the mid-hindbrain junction region in E8.5 to E12.5 transgenic embryos. These results provided molecular and genetic evidence that the Pax genes are immediately upstream of En2 in the genetic cascade controlling early regional development of the mouse midbrain and anterior hindbrain. Analysis of expression of the three zebra®sh En genes in noi mutants showed that expression of the En genes was not initiated (Brand et al., 1996) . Thus, in zebra®sh, Pax2.1 is required for initiation of expression of the En genes. In mouse, En2 expression was found to be missing in Pax2/5 double mutants by E9.5 when a morphological deletion is apparent, but analysis of their initial expression at E8.0 was not reported (Schwarz et al., 1999) .
In the present study, we further tested the functional requirement of the two Pax2/5/8-binding sites found in the En2CX enhancer sequence in regulating endogenous En2 expression through a gene targeting approach. A targeted deletion of the two Pax2/5/8-binding sites in the En2 locus was generated by homologous recombination in mouse embryonic stem (ES) cells. In situ hybridization analysis of En2 RNA from the mutant allele showed that deletion of the two DNA-binding sites reduced the number of cells expressing En2 in the presumptive mid-hindbrain region at the 5-7 somite stage, demonstrating that these two Pax2/5/8-binding sites are required for proper initiation of En2 expression. However, this deletion mutation had no obvious effect on En2 expression in the midbrain-brain region at later stages (E9.0 onwards). These results suggest that the Pax2/5/8-binding sites are not critically required for maintaining En2 expression, and that other regulatory sequences, possibly including additional Pax2/5/8-binding sites, are required to fully activate and then maintain En2 expression. Consistent with these results, re-evaluation of lacZ RNA expression, rather than b-galactosidase (b-gal) protein activity, from the En2CX/lacZ transgene showed that the 1.0 kb En2CX enhancer fragment can drive En2-like transcription most accurately only at the earliest, but not later, stages.
Results

Generation of mice with a targeted deletion of two Pax2/5/8-binding sites in the En2 locus
In order to determine whether the two essential Pax2/5/8-binding sites identi®ed in the 1.0 kb En2CX enhancer fragment in our previous transgenic experiments (Song et al., 1996) were also necessary for expression of the endogenous En2 gene in the normal genomic environment, mice were generated carrying a targeted deletion of the two Pax-binding sites by homologous recombination in ES cells (see Materials and Methods) . A positive/negative targeting vector (Mansour et al., 1988 ) containing 1.8 kb of 5 H and 7.2 kb of 3 H En2 genomic sequences was constructed to replace the two adjacent DNA-binding sites (66 bp) with a loxP/PGKneo cassette (Fig. 1A) . A targeted allele with such sequences is referred to as En2 pbdneo (En2 Pax2/5/8-binding sites deletion with neo). pbd heterozygous mice. PCR ampli®ed a 382 bp wild type fragment and a 436 bp mutant fragment which contains the additional HindIII site. Half of the PCR products were cut with HindIII, and the mutant fragment was cut into two subfragments of 224 bp and 212 bp. A, AccI; B, BamHI; C,ClaI; E, EcoRI; H, HindIII; K, KpnI; X, XhaI; Xh, XhoI; uc, uncut; ct, cut.
Two R1-derived and two W4-derived chimeric males carrying the En2 pbdneo allele were bred to 129/SvEv females to establish F0 heterozygotes. Subsequently, the 4 targeted mouse lines were kept on a CD1 outbred background. Intercrossing of heterozygotes produced En2 pbdneo homozygous mice that were viable and fertile. This was expected since En2 null homozygotes are viable and fertile . The analysis reported here is primarily from one W4-derived mouse line (20-5).
En2 expression in En2
pbdneo mutant embryos To determine whether the two Pax2/5/8-binding sites were required for expression of the endogenous En2 gene, we examined En2 expression in E8.5-E17.5 En2 pbdneo homozygous mutant embryos by RNA in situ hybridization analysis. In wild type embryos, the En2 gene is ®rst detected in two triangular patches of cells within the anterior neuroepithelium at the 5-7 somite stage (E8.5; Fig. 2A ). After the neural tube closes (E9.5-E10.5) En2 is expressed in a broad band of cells spanning the mid-hindbrain region (Fig. 2C,E) . In E8.5 En2 pbdneo homozygous mutant embryos (n 5), En2 RNA expression (Fig. 2B ) was signi®cantly weaker than that seen in wild type embryos. In E9.5 (n 6) and E10.5 (n 6) homozygous mutant embryos, the En2 expression was essentially normal in pattern, but a reduction in strength of expression was consistently observed (Fig. 2D,F) . No change in En2 expression was observed in E12.5 (n 3), E15.5 (n 3) and E17.5 (n 3) homozygous mutant embryos as compared to wild types (data not shown).
pbd mutant embryos The reduction in En2 expression observed in En2 pbdneo mutants could result from the deletion of the two Pax2/5/ 8-binding sites. Alternatively, or in addition, it could be due to the insertion of the PGKneo cassette into the En2 regulatory region. Interference by an inserted neo promoter on an adjacent gene's promoter has been reported in other loci (reviewed in Olson et al., 1996) . To address this issue, the En2 pbdneo mice were crossed with transgenic mice carrying a CMV/cre transgene (see Materials and Methods) to obtain in vivo cre-loxP-mediated excision of the PGKneo cassette. In the double transgenic offspring from such crosses, the targeted En2 allele, En2 pbd (En2 Pax2/5/8-binding sites deletion), contains a single 34 bp loxP site plus 86 bp of polylinker sequences in place of the 66 bp region containing the two Pax2/5/8-binding sites (Fig. 1A) . En2 pbd heterozygotes were intercrossed to produce mice homozygous for the En2 pbd allele that were viable and fertile. En2 expression in En2 pbd homozygous mutants was analyzed from E8.5 to E17.5 by RNA in situ hybridization analysis. In wild type embryos En2 expression is activated in the anterior neuroepithelium at the 5-7 somite stage (E8.5, Fig. 3A ). In contrast, in the En2 pbd homozygous embryos of the same stage (n 4) only weak En2 RNA signals were detected in the most anterior part of the normal En2 expression domain (Fig. 3B) . As development proceeded, at the 11-14 somite stage (E9.0), En2 expression in mutant embryos (n 3, Fig. 2D ) appeared similar to that seen in the wild type embryos (Fig. 3C) . Later in development, at E9.5 (n 4, Fig. 3E,F) , E10.5, E12.5 and E17.5 (n 3 for each stage, data not shown) no detectable differences in En2 expression patterns were observed between mutant and wild type embryos. These results indicate that deletion of the Pax2/5/8-binding sites affected initiation of En2 expression but not later expression, and that the reduction of En2 expression observed in E9.5-E10.5 En2 pbdneo homozygous embryos was due to the presence of PGKNeo in the En2 5' regulatory region.
Brain morphology of En2
pbdneo/pbdneo , En2 pbd/pbd and En2 pbd/ntd mutants Ablation of En2 expression speci®cally affects cerebellum development Millen et al., 1994) . pbneo/ndt , also appeared normal (n 4, data not shown). These results suggest that a more than 50% reduction in the En2 expression levels between E8.5 and E10.5 does not affect normal cerebellar development.
In homozygous
En2 mutant mice (En2 ntd ), the size of the cerebellum
Expression patterns of endogenous
pbd gene targeting experiments showed that deletion of the Pax2/5/8-binding sites from the endogenous En2CX enhancer region only transiently affected initiation of En2 expression but had no detectable effect on En2 expression at later stages. This is in contrast to our previous transgenic analysis in which deletion of the two Pax2/5/8-binding sites in the context of the 1.0 kb En2CX enhancer completely abolished the enhancer activity in directing En2-like early embryonic lacZ expression from E8.5 to E12.5 (Song et al., 1996) . There are several possible explanations for this difference (see Section 3), one of them being that the En2CX enhancer does not actually act in an En2-like manner as shown by b-gal activity. Consistent with this, in another transgenic experiment a 2.5 kb En2 enhancer that included the 1.0 kb En2CX enhancer was found to direct cre RNA expression in only a narrow domain at the junction between the mid brain and hindbrain (Zinyk et al., 1998) . Two factors which could account for the discrepancy between our studies with a lacZ and cre En2CX transgene are: RNA in situ hybridization analysis could be less sensitive than b-gal activity in detecting transgene expression, or, the lacz and cre RNA and/or protein have different stabilities. If the latter is the case, it is possible that lacz protein is more stable than cre and thus b-gal activity would be detected in cells that express lacZ RNA at the stage of analysis, as well as in cells many hours after lacZ is not being transcribed. This raised an important question as to whether the lacZ staining pattern previously observed in the En2CX/lacZ transgenic embryos only re¯ected de novo transgene transcription or was also acting as a short term lineage marker for cells that had expressed lacZ RNA/ protein.
To address this issue, we compared the patterns of expression of lacZ RNA and lacZ protein directed by the same transgene. Transgenic embryos derived from mice homozy- gous for one of our En2CX/lacZ transgenic lines were obtained and half of the embryos were assayed by RNA in situ hybridization and the other half by X-gal staining. In order to compare the sensitivities of the RNA in situ hybridization and X-gal staining methods, we examined the expression patterns of lacZ RNA and X-gal staining at E8.5, since at this stage the transgene expression is ®rst initiated and thus there should be little in¯uence of RNA and protein stability. At this stage the staining patterns of lacZ RNA (n 4, Fig. 4B ) and X-gal (n 4, Fig. 4C) were similar to each other, indicating that these two methods have comparable sensitivities. However, at E9.0 (11-14 somites) the expression domain of En2CX/lacZ RNA (n 4, Fig.  4E ) was signi®cantly smaller than the En2CX/lacZ X-gal staining pattern (n 5, Fig. 4F ), and the difference became even more pronounced at E9.5 (n 4 for each group, Fig.  4H,I ). At E10.5 and later, only a small number of transgene expressing cells could be detected at the dorsal mid-hindbrain junction region by RNA in situ analysis (n 3, Fig.  4K ). However, a broad band of cells spanning the junction were still detected by X-gal staining (n 2, Fig. 4L ). These results demonstrate that lacZ protein has a signi®cantly longer half life than lacZ RNA. It is worth noting that the mRNA expression patterns of lacZ and cre directed by the 1.0 and 2.5 kb En2 enhancers, respectively, were very similar to each other, indicating that the lacZ and cre mRNA have a similar half life.
Taken together, data from the comparative analysis of Lacz RNA and protein expression indicate that b-gal activity does not accurately re¯ect transcription from the transgene at any given stage, and that lacZ RNA transcripts appear to be a better indicator of a lacZ transgene expression pattern. We therefore re-evaluated the regulatory activity of the En2CX enhancer by comparing the expression of En2CX/lacZ RNA and endogenous En2 RNA. At E8.5, En2CX/lacZ RNA (n 4, Fig. 4B ) and En2 RNA (Fig.  4A) showed very similar expression patterns. At E9.0 (n 4) and E9.5 (n 3), the En2lacZ RNA expression domains (Fig. 4E,H) were signi®cantly smaller than the endogenous En2 expression pattern (Fig. 4D,G) . At E10.5 (n 3, Fig. 4K ) and E12.5 (data not shown) the transgene expression was restricted to a small dorsal patch at the midhindbrain junction region, but at these stages endogenous En2 expresses broadly in the mid-hindbrain region (E10.5, n 4, Fig. 4J ). These results indicate that the regulatory elements contained in the 1.0 kb En2CX enhancer are suf®-cient to initiate transgene expression in an En2-like manner. The regulatory sequences are also capable of directing transgene expression to the mid-hindbrain junction region up to E12.5. However, they are not suf®cient to direct expressions in a pattern that closely mimics the endogenous En2 expression pattern from E9.0 onwards. This conclusion is consistent with our gene targeting experiment in that the main regulatory requirement for the two Pax2/5/8-binding sites in the 1.0 kb enhancer sequence is for initiation of En2 midhindbrain expression.
Discussion
In this study we tested the functional requirement of the two Pax2/5/8 DNA-binding sites in a 5 H En2CX enhancer region for regulating endogenous En2 expression using a Cre-loxP gene targeting strategy. Deletion of the two binding sites from the En2 locus disturbed initiation of En2 expression in the presumptive mid-hindbrain junction region at the 5±7 somite stage. This demonstrates a role for the two DNA-binding sites in activating En2 transcription. This mutation, however, did not completely abolish En2 activation at E8.5, nor did it affect expression at later stages, demonstrating that these binding sites alone are not critically required for En2 expression. Since this result appeared different from the one obtained in our previous transgenic study, we re-evaluated the expression pattern of a lacZ reporter gene directed by the enhancer fragment containing the Pax2/5/8 binding sites using RNA in situ hybridization analysis. The lacZ RNA expression was found to be similar to that of endogenous En2 RNA only at E8.5. In contrast, unlike b-gal activity, lacZ RNA was only detected in a much more restricted domain than normal En2 RNA at later stages. This comparative expression analysis indicates that the stable lacZ protein was acting as a transient lineage marker, and as such led to an overrepresentation of the cell population transcribing the lacZ reporter gene. Thus, the in vivo gene targeting results of deletion of Pax2/5/8-binding sites are consistent with the actual regulatory function of the En2CX enhancer fragment that requires the Pax2/5/8-binding sites for activity.
Pax2/5/8-binding sites are involved in initiation of En2 expression but are not essential for early embryonic En2 expression
During development, En2 shows spatially and temporally regulated expression in the presumptive midbrain and cerebellum. En2 expression can be divided into at least three phases: early embryonic regionally restricted expression in the mid-hindbrain region (E8.5±E12.5); late embryonic expression in speci®c cell-types in the midbrain and domain-restricted cerebellar expression (E12.5-®rst week postnatal); and adult cell-type-speci®c expression in midbrain structures and the cerebellum. Our previous transgenic analyses have shown that the different phases of En2 expression involve different sets of cis-acting DNA regulatory elements. A 9.5 kb genomic fragment is suf®cient for conferring an En2-like expression pattern throughout development (Logan et al., 1993) . A 1.0 kb subfragment from the 9.5 kb region, located 5.8 kb 5
H of the start of En2 transcription, seemed initially to be capable of initiating and maintaining the early transgene expression in the mid-hindbrain junction region (up to E12.5), but not for later phases of expression (Song et al., 1996) . A systematic functional analysis of the 1.0 kb enhancer in transgenic mice revealed that the 1.0 kb enhancer contains multiple positive and negative DNA regulatory elements: a 5 H 460 bp En2 speci®c mid-hindbrain enhancer element, a middle 240 bp general enhancer element and a 3 H 300 bp repressor element, that all function in concert to establish the early mid-hindbrain expression. In vitro biochemical and sequence analyses of the 1.0 kb enhancer identi®ed two Pax2/5/8-binding sites located in the 5 H En2 mid-hindbrain speci®c enhancer element. Mutagenesis and transgenic assays showed that the Pax2/5/8-binding sites are essential for the regulatory activity of the 1.0 kb enhancer (Song et al., 1996) .
In the present study we further addressed the functional role of the Pax2/5/8-binding sites in directing endogenous En2 expression. In En2 pbd homozygous mutant embryos that lack these sites, En2 expression was activated at the right time, the 5±7 somite stage (E8.5), but its expression domain in the presumptive mid-hindbrain region was reduced as compared to wild type embryos. This effect was transient, since by the 11±14 somite stage (E9.0) onwards the mutant and wild type embryos showed comparable En2 expression patterns. These results demonstrate that these Pax2/5/8-binding sites are involved in initiation of En2 expression but are not critically required for fully activating and maintaining En2 expression.
During early mouse brain development, Pax2, Pax5 and Pax8 expression signi®cantly overlaps with En in the midhindbrain region from E8.5 to E12.5. Moreover, in zebra®sh eng-2 expression is completely lost in noi mutant embryos that contain a mutation in pax2a (Brand et al., 1996) , demonstrating that the Pax genes play an important role in En expression in the mid-hindbrain region of another vertebrate. Since deletion of the two Pax2/5/8-binding sites from the mouse En2 locus only has a partial effect on initiation of En2 expression, it is possible that proteins other than Pax2/ 5/8 regulate En2 expression and/or that there are other Pax2/ 5/8-binding sites in the En2 locus located outside the 1.0 kb enhancer region that normally play a role in En2 transcription. Consistent with both these possibilities, our previous transgenic study (Song et al., 1996) showed that a single copy of the 460 bp 5 H En2 speci®c enhancer element, which contains the two Pax2/5/8-binding sites, could only direct a low level of b-gal activity in a very restricted domain in the dorsal mid-hindbrain junction. However, a high level of bgal activity, which gave rise to a broad mid-hindbrain domain of lacZ protein, was conferred by two copies of the enhancer element or by the combination of the 5' En2 speci®c enhancer element with the middle 240 bp general transcriptional enhancer element. These transgenic studies indicate that during normal development the endogenous En2 mid-hindbrain expression is established through the cooperative actions of multiple enhancer elements that could include many Pax-binding sites.
In En2CX/lacZ transgenics LacZ protein acts as a lineage tracer
In this study we compared the developmental expression pro®les of lacZ RNA and protein directed by a 1.0 kb En-2 enhancer fragment. At E8.5, when the transgene was ®rst expressed, the patterns of RNA expression and X-gal staining were quite similar. However, from E9.0 onwards, the transgene expression domain detected by X-gal staining was signi®cantly broader than that detected by RNA in situ analysis. The difference became more pronounced as development proceeded. At E10.5, a broad band of X-gal staining cells was still readily seen in the mid-hindbrain junction region, whereas only a very narrow band of cells were positive for lacZ RNA. The difference in expression patterns is not likely to be primarily due to different sensitivities of the two detection methods, because both methods detected similar transgene expression patterns at E8.5 when transgene expression is initiated. In addition, a 2.5 kb En2 enhancer has been used in another transgenic study for directing expression of cre (Zinyk et al., 1998) and the RNA expression pattern was very similar to the lacZ RNA pattern in the En2CX/lacZ transgenic embryos, indicating that the half life of lacZ mRNA is comparable to that of cre mRNA. Thus, the most likely explanation for the difference in lacZ RNA and protein is that lacZ protein has a longer half life than lacZ RNA. It should be pointed out that in our previous studies (Logan et al., 1993 ) a 9.5 kb enhancer fragment was analyzed, and it is possible that this fragment directs expression more similar to En2, especially as it expresses into adulthood.
From E8.5 to E10.5, the mid-hindbrain junction region, like other brain regions, undergoes rapid cell proliferation. It has been shown in the chick that there are morphogenetic movements of cells in the isthmus region that translocate dorsal cells anteriorly and posteriorly for long distances (Millet et al., 1996) . The broad X-gal staining pattern observed with the En2CX/lacZ transgene likely re¯ects similar morphogenetic movements in the mouse with stable lacZ protein acting as a transient lineage marker. These results are consistent with fate mapping studies using a site speci®c recombination approach in which cells expressing cre from the 2.5 kb En2 enhancer were found to populate large regions of the midbrain and cerebellum (Zinyk et al., 1998) . Thus, X-gal staining of transgenic embryos can mark two different cell populations, the cells that express the transgene at the stage analyzed and the cells that have expressed the transgene previously. This can lead to X-gal staining giving an apparently broader transgene expression domain and longer expression time than actual transcription.
Our comparative expression analysis raises several important issues regarding the use of X-gal staining, a very commonly used method, to assay lacZ reporter transgene expression in vivo. First, it is not suitable for determining when transcription of a transgene is turned off due to the long half life of lacZ protein. Second, caution should be taken in interpreting a pattern of transgene expression in a region that has rapid cell proliferation and/or substantial cell movement because in these situations X-gal staining acts as a lineage marker rather than a re¯ection of de novo reporter gene expression. A possible example of this situation comes from a study of Wnt1 regulatory sequences in which a Wnt1/ lacZ transgene was found to be expressed in migrating neural crest cells, whereas Wnt1 RNA was only detected in the dorsal neural tube (Echelard et al., 1994) .
Due to our ®nding that lacZ protein is not a reliable marker for transcription, it was necessary to re-evaluate the regulatory activity of the 1.0 kb En2 mid-hindbrain enhancer using RNA in situ hybridization analysis. According to the lacZ and cre RNA expression patterns, the 2.5 and 1.0 kb enhancers contain suf®cient regulatory sequences to initiate En2-like transgene expression in the presumptive mid-hindbrain junction region at E8.5 and to direct transgene expression in the correct spatial domain surrounding the mid-hindbrain junction up to E12.5. However, from E9.0 to E12.5 the transgene expression domain is not as broad as the endogenous En2 expression domain, indicating that these enhancers only contain a subset of the regulatory elements that are responsible for early embryonic En2 expression in the brain. This regulatory activity pro®le is in agreement with the result obtained from our gene targeting experiment in that only the initiation of En2 expression and not later expression was affected by deletion of the Pax2/5/8-binding sites. heterozygote crosses were genotyped by PCR using yolk sac DNA. Tissue samples were digested at 608C for 6±8 h in a non-ionic detergent proteinase K buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 2.0 mM MgCl 2 , 0.1 mg/ml gelatin (Sigma), 0.45% Nonidet P-40 (Sigma), 0.45% Tween-20 (Sigma) and 0.005% proteinase K (Sigma). The digested samples were denatured at 948C for 10 min and then ampli®ed by PCR for 30 cycles (948C, 1 min; 558C, 1 min; 728C, 1 min). PCR ampli®ed fragments were visualized by 2.7% agarose gel electrophoresis and ethidium bromide staining. The wild type allele was detected as a 382 bp fragment (Fig. 1D ) using a pair of En2 speci®c primers: sense strand 5
H -CTTTGTGATGAGGGCATGT-TACTG-3 H (a; Fig. 1 ) and antisense strand 5 H -CCAAT-GAGCGGCTGCTATAAGTG-3
H . In the En2 pbdneo allele, PGKNeo was inserted into the ampli®ed region and therefore was not ampli®ed with the PCR conditions used. The En2 pbdneo mutant allele was detected as a 230 bp fragment (Fig. 1D ) using a set of neo speci®c primers: sense strand 5 H -GAACAAGATGGATTGCACGCAG, and antisense strand 5 H -TTCAGTGACAACGTCGAGCACA (b; Fig. 1 ). The En2 pbd allele was ampli®ed as a 436 bp fragment (Fig. 1E ) using the En2 speci®c primers. Furthermore, the 436 bp mutant fragment could be cut at the extra HindIII site to generate two subfragments of 212 and 224 bp (Fig. 1E). 4.4. Whole-mount RNA in situ hybridization analysis and lacZ staining for b-gal activity Mid-day of the day on which the vaginal plug was detected was considered as day 0.5 post coitum in the staging of embryos (E0.5). For whole mount RNA in situ hybridization, whole embryos, or dissected brains from embryos older than E10.5, were ®xed overnight in 4% paraformaldehyde at 48C. Whole-mount RNA in situ hybridization of embryos was performed as described (Parr et al., 1993) , with modi®cations (Knecht et al., 1995) . The staining patterns were observed after 1 h of staining, and the color reaction was stopped after 6±8 h of staining. The wholemount RNA in situ photos shown were taken from embryos after the color staining was completed. Single-stranded RNA probes labeled with digoxigenin-UTP were synthesized from linearized template DNA as directed by the manufacturer (Boehringer Mannhein Biochemicals). Two En2 probes containing a 800 bp BgII/XbaI fragment within the 3 H untranslated region (Millen et al., 1994) and a 600 bp XhoI-ClalI fragment within the coding region were used for RNA in situ hybridization analyses. The two probes produced comparable En2 RNA expression patterns in wild type embryos (Wolf and Joyner, unpublished results). The BgII/XbaI fragment was employed in experiments using the En2 pbdneo and En2 pbd alleles. The XhoI-ClalI fragment was employed in experiments using the En2 pbd/ntd allele since this probe is derived from sequences deleted from the En2 ntd allele (Millen et al., 1994) . The lacZ probe contained a 800 bp EcoRV/SacI fragment. b-gal activity was assayed by whole-mount X-gal (5-bromo-4-choro-3-indolyl b-D-galactopyranoside) staining as described (Logan et al., 1993) .
